TCF Ep. 521 - Stephen Wilkes
The Candid Frame: Conversations on Photography - Podcast tekijän mukaan Ibarionex R. Perello
Kategoriat:
Since opening his studio in New York City in 1983, photographer Stephen Wilkes has built an unprecedented body of work and a reputation as one of America’s most iconic photographers, widely recognized for his fine art, editorial and commercial work. Wilkes’ early career interpretations of Mainland China, California’s Highway One, and impressionistic “Burned Objects” set the tone for a series of career-defining projects that catapulted him to the top of the photographic landscape. Day to Night, Wilkes’ most defining project, began in 2009. These epic cityscapes and landscapes, portrayed from a fixed camera angle for up to 30 hours capture fleeting moments of humanity as light passes in front of his lens over the course of a full day. Blending these images into a single photograph takes months to complete. Day to Night has been featured on CBS Sunday Morning as well as dozens of other prominent media outlets and, with a grant from the National Geographic Society, was recently extended to include America’s National Parks in celebration of their centennial anniversary and Bird Migration for the 2018 Year of the Bird. Day to Night: In the Field with Stephen Wilkes was exhibited at The National Geographic Museum in February 2018. Photographer Links: Stephen Wilkes Jay Myself Film Jay Maisel Girault de Prangey Education Resources: Creating Personal Breakthroughs Tokyo: Exploration of the Metropolis 2.0 Momenta Photographic Workshops https://momentaworkshops.com/workshops/ Candid Frame Resources Making Photographs: Developing a Personal Visual Workflow Download the free Candid Frame app for your favorite smart device. Click here to download for . Click here to download Support the work we do at The Candid Frame with contributing to our Patreon effort. You can do this by visiting or visiting the website and clicking on the Patreon button. You can also provide a one-time donation via . You can follow Ibarionex on and .